-
Product Insights
Puget Sound Refinery, United States
Puget Sound refinery is located in Washington, United States. The refinery is owned by HF Sinclair Corp. It is operated by HF Sinclair Corp. The project started its operations in 1958. Puget Sound Refinery profile includes core details such as name, location, refinery type, asset status, start year, owner and equity stakes, operator, design/nameplate capacities of different processing units for the period 2010-2030, nelson complexity index (NCI) and capex. We also provide refinery maintenance information for active refineries (both historic...
-
Company Profile
![]()
Puget Energy Inc – Company Profile
Puget Energy Inc (Puget Energy), a subsidiary of Puget Holdings LLC, is an energy services company. It generates, transmits, and distributes electricity and distributes natural gas. Puget Energy operates through its regulated energy subsidiary, Puget Sound Energy Inc (PSE). The company provides electricity and natural gas service to residential, commercial, and industrial customers in various counties across the state of Washington primarily in the Puget Sound region. Through its wholly owned, non-regulated subsidiary Puget LNG LLC, Puget Energy also owns,...
Add to Basket -
Company Insights
![]()
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-10H in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.E-10H in Gastric CancerDrug Details:E-10H is under development for the treatment of gastric cancer, colorectal cancer...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PTC-518 in Huntington Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PTC-518 in Huntington DiseaseDrug Details:PTC-518 is under development for the treatment of Huntington disease. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Myelofibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GB-2064 in Myelofibrosis Drug Details:GB-2064 (PAT-1251) Is under development for the treatment of primary myelofibrosis and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Xalnesiran Sodium in Hepatitis B
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Xalnesiran Sodium in Hepatitis B Drug Details: Xalnesiran sodium is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KB-001 in Oral Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.KB-001 in Oral CancerDrug Details:KB-001 is under development for the treatment of Alzheimer's disease, nonalcoholic fatty...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SYN-020 in Enteritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SYN-020 in EnteritisDrug Details:SYN-020 is under development for the treatment of enterocolitis associated with radiation therapy,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SP-0125 in Respiratory Syncytial Virus (RSV) Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SP-0125 in Respiratory Syncytial Virus (RSV) InfectionsDrug Details:SP-0125 is under development for the prevention of respiratory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CRD-740 in Diastolic Heart Failure
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CRD-740 in Diastolic Heart FailureDrug Details:CRD-740 is under development for the treatment of heart failure with reduced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Annexuzlimab in Bladder Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Annexuzlimab in Bladder Cancer Drug Details:Annexuzlimab is under development for the treatment of autoimmune diseases including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KB-001 in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.KB-001 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:KB-001 is under development for the treatment of Alzheimer's disease, nonalcoholic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BSI-060T in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BSI-060T in Colorectal Cancer Drug Details:BSI-060T is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMT-009 in Burkitt Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMT-009 in Burkitt Lymphoma Drug Details: IMT-009 is under development for the treatment solid tumors and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ONC-392 in Metastatic Renal Cell Carcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Metastatic Renal Cell Carcinoma Drug Details: ONC-392 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selicrelumab in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Selicrelumab in Metastatic Colorectal Cancer Drug Details:Selicrelumab is under development for the treatment of recurrent or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PSB-202 in Chronic Lymphocytic Leukemia (CLL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PSB-202 in Chronic Lymphocytic Leukemia (CLL) Drug Details:PSB-202 is under development for the treatment of follicular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eftozanermin Alfa in Diffuse Large B-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Eftozanermin Alfa in Diffuse Large B-Cell Lymphoma Drug Details:Eftozanermin alfa (ABBV-621) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PSB-202 in Follicular Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PSB-202 in Follicular Lymphoma Drug Details:PSB-202 is under development for the treatment of follicular lymphoma, chronic...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.